JP2016503793A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016503793A5 JP2016503793A5 JP2015549643A JP2015549643A JP2016503793A5 JP 2016503793 A5 JP2016503793 A5 JP 2016503793A5 JP 2015549643 A JP2015549643 A JP 2015549643A JP 2015549643 A JP2015549643 A JP 2015549643A JP 2016503793 A5 JP2016503793 A5 JP 2016503793A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- compound
- acceptable salt
- optionally substituted
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010002091 Anaesthesia Diseases 0.000 claims 1
- 230000037005 anaesthesia Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical group NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261738822P | 2012-12-18 | 2012-12-18 | |
| US61/738,822 | 2012-12-18 | ||
| PCT/US2013/076214 WO2014100228A1 (en) | 2012-12-18 | 2013-12-18 | Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019109822A Division JP6852118B2 (ja) | 2012-12-18 | 2019-06-12 | 向神経活性１９−アルコキシ−１７−置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016503793A JP2016503793A (ja) | 2016-02-08 |
| JP2016503793A5 true JP2016503793A5 (enExample) | 2017-02-02 |
| JP6542127B2 JP6542127B2 (ja) | 2019-07-10 |
Family
ID=50979162
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015549643A Active JP6542127B2 (ja) | 2012-12-18 | 2013-12-18 | 向神経活性１９−アルコキシ−１７−置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
| JP2019109822A Active JP6852118B2 (ja) | 2012-12-18 | 2019-06-12 | 向神経活性１９−アルコキシ−１７−置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
| JP2021038515A Active JP7241792B2 (ja) | 2012-12-18 | 2021-03-10 | 向神経活性１９－アルコキシ－１７－置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
| JP2023034402A Active JP7589275B2 (ja) | 2012-12-18 | 2023-03-07 | 向神経活性１９－アルコキシ－１７－置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
| JP2024197865A Pending JP2025024078A (ja) | 2012-12-18 | 2024-11-13 | 向神経活性１９－アルコキシ－１７－置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019109822A Active JP6852118B2 (ja) | 2012-12-18 | 2019-06-12 | 向神経活性１９−アルコキシ−１７−置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
| JP2021038515A Active JP7241792B2 (ja) | 2012-12-18 | 2021-03-10 | 向神経活性１９－アルコキシ－１７－置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
| JP2023034402A Active JP7589275B2 (ja) | 2012-12-18 | 2023-03-07 | 向神経活性１９－アルコキシ－１７－置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
| JP2024197865A Pending JP2025024078A (ja) | 2012-12-18 | 2024-11-13 | 向神経活性１９－アルコキシ－１７－置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
Country Status (27)
| Country | Link |
|---|---|
| US (7) | US9676812B2 (enExample) |
| EP (3) | EP3392260B1 (enExample) |
| JP (5) | JP6542127B2 (enExample) |
| KR (3) | KR102265408B1 (enExample) |
| CN (3) | CN105026415B (enExample) |
| AU (5) | AU2013361485B2 (enExample) |
| BR (1) | BR112015014397B1 (enExample) |
| CA (1) | CA2895513C (enExample) |
| CY (1) | CY1121150T1 (enExample) |
| DK (1) | DK2935307T3 (enExample) |
| ES (2) | ES2933987T3 (enExample) |
| HR (1) | HRP20181048T1 (enExample) |
| HU (1) | HUE039057T2 (enExample) |
| IL (3) | IL278396B2 (enExample) |
| LT (1) | LT2935307T (enExample) |
| MX (2) | MX365644B (enExample) |
| NZ (2) | NZ739760A (enExample) |
| PH (2) | PH12018502141A1 (enExample) |
| PL (1) | PL2935307T3 (enExample) |
| PT (2) | PT2935307T (enExample) |
| RS (1) | RS57390B1 (enExample) |
| RU (1) | RU2663665C2 (enExample) |
| SG (3) | SG11201504848QA (enExample) |
| SI (2) | SI3392260T1 (enExample) |
| SM (1) | SMT201800422T1 (enExample) |
| TR (1) | TR201808616T4 (enExample) |
| WO (1) | WO2014100228A1 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120107533A (ko) | 2005-11-28 | 2012-10-02 | 마리누스 파마슈티컬스 | ｇａｎａｘｏｌｏｎｅ 제형, 이의 제조방법 및 용도 |
| CN107936076B (zh) | 2011-09-08 | 2021-10-15 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
| AU2012323888A1 (en) | 2011-10-14 | 2014-05-29 | Sage Therapeutics, Inc. | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| HRP20192348T1 (hr) | 2012-01-23 | 2020-03-20 | Sage Therapeutics, Inc. | Formulacije neuroaktivnog steroida koje uključuju kompleks alopregnanolona i sulfobutil eter beta-ciklodekstrina |
| KR102121633B1 (ko) | 2012-08-21 | 2020-06-10 | 세이지 테라퓨틱스, 인크. | 간질 또는 간질지속 상태를 치료하는 방법 |
| HRP20181048T1 (hr) | 2012-12-18 | 2018-08-24 | Washington University | Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja |
| ES2699445T3 (es) | 2013-03-13 | 2019-02-11 | Sage Therapeutics Inc | Esteroides neuroactivos y métodos de utilización de los mismos |
| HUE051403T2 (hu) | 2013-04-17 | 2021-03-01 | Sage Therapeutics Inc | Neuroaktív 19-nor-szteroidok kezelési eljárásokhoz |
| WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| EP2986623B1 (en) | 2013-04-17 | 2018-11-07 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof |
| US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
| LT3021852T (lt) | 2013-07-19 | 2021-04-12 | Sage Therapeutics, Inc. | Neuroaktyvūs steroidai, jų kompozicijos ir panaudojimas |
| EP3035940B1 (en) | 2013-08-23 | 2018-10-17 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| EP3157528B1 (en) | 2014-06-18 | 2023-09-13 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| EP3206493B1 (en) | 2014-10-16 | 2020-05-06 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| CN112961206A (zh) | 2014-10-16 | 2021-06-15 | 萨奇治疗股份有限公司 | 靶向cns障碍的组合物和方法 |
| HUE049014T2 (hu) | 2014-11-27 | 2020-09-28 | Sage Therapeutics Inc | Készítmények és módszerek a központi idegrendszer rendellenességeinek kezelésére |
| ES2857082T3 (es) * | 2015-01-26 | 2021-09-28 | Sage Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos del SNC |
| US10329320B2 (en) | 2015-02-20 | 2019-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| MA45276A (fr) | 2015-06-18 | 2018-04-25 | Sage Therapeutics Inc | Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation |
| HK1255500A1 (zh) | 2015-07-06 | 2019-08-16 | Sage Therapeutics, Inc. | 氧固醇及其使用方法 |
| KR20240137111A (ko) | 2015-07-06 | 2024-09-19 | 세이지 테라퓨틱스, 인크. | 옥시스테롤 및 그의 사용 방법 |
| US11117924B2 (en) | 2015-07-06 | 2021-09-14 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| EP3362042A1 (en) | 2015-10-16 | 2018-08-22 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| MA43284A (fr) * | 2015-11-20 | 2018-09-26 | Sage Therapeutics Inc | Composés et leurs méthodes d'utilisation |
| CA3017172C (en) | 2016-03-08 | 2023-03-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| CA3019146C (en) | 2016-04-01 | 2024-03-26 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| LT3481846T (lt) | 2016-07-07 | 2021-08-25 | Sage Therapeutics, Inc. | 11-pakeistieji 24-hidroksisteroliai, skirti naudoti gydant su nmda susijusias būkles |
| NZ790187A (en) | 2016-07-11 | 2025-08-29 | Sage Therapeutics Inc | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| NZ790225A (en) | 2016-07-11 | 2025-08-29 | Sage Therapeutics Inc | C17, C20, and C21 substituted neuroactive steroids and their methods of use |
| CN119112906A (zh) | 2016-08-11 | 2024-12-13 | 奥维德医疗公司 | 用于治疗癫痫性紊乱的方法和组合物 |
| IL315950A (en) | 2016-08-23 | 2024-11-01 | Sage Therapeutics Inc | 19-NOR C3, 3-Dimuter C21-N-Pyrazolyl Steroid Crystalline |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| WO2018064649A1 (en) | 2016-09-30 | 2018-04-05 | Sage Therapeutics, Inc. | C7 substituted oxysterols and methods as nmda modulators |
| MA46565A (fr) | 2016-10-18 | 2019-08-28 | Sage Therapeutics Inc | Oxystérols et leurs procédés d'utilisation |
| MX2019004578A (es) | 2016-10-18 | 2019-10-09 | Sage Therapeutics Inc | Oxisteroles y metodos de uso de los mismos. |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| CN109988210B (zh) * | 2017-12-30 | 2022-05-17 | 天津药业研究院股份有限公司 | 一种黄体酮和黄体酮中间体的制备方法 |
| DK3864022T3 (da) | 2018-10-12 | 2023-12-18 | Sage Therapeutics Inc | Neuroaktive steroider substitueret i Position 10 med en cyklisk gruppe til anvendelse til behandlingen af CNS-lidelser |
| CN109289095B (zh) * | 2018-11-23 | 2021-03-26 | 淮海工学院 | 一种含盐酸利多卡因的肠镜凝胶剂及其制备方法 |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| CN114206900A (zh) | 2019-05-31 | 2022-03-18 | 萨奇治疗股份有限公司 | 神经活性类固醇及其组合物 |
| JP7754799B2 (ja) | 2019-08-05 | 2025-10-15 | マリナス ファーマシューティカルズ， インコーポレイテッド | てんかん重積状態の治療に使用するためのガナキソロン |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| EP4072559A4 (en) | 2019-12-06 | 2023-06-21 | Marinus Pharmaceuticals, Inc. | GANAXOLONE FOR USE IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX |
| PE20221911A1 (es) | 2020-03-25 | 2022-12-23 | Sage Therapeutics Inc | Uso de agentes para el tratamiento de condiciones respiratorias |
| CN117801047B (zh) * | 2023-01-19 | 2024-12-20 | 北京华睿鼎信科技有限公司 | 神经甾体衍生物及其用途 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB820780A (en) * | 1954-12-08 | 1959-09-23 | Syntex Sa | Cyclopentanophenanthrene derivatives |
| US2856415A (en) * | 1957-11-13 | 1958-10-14 | Searle & Co | 3,19-dihydroxy-5-androstene derivatives |
| BE632431A (enExample) * | 1962-05-16 | |||
| US3206459A (en) * | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| US4239681A (en) * | 1974-04-15 | 1980-12-16 | Richardson-Merrell Inc. | Androst-4-en-19-ols |
| US4071625A (en) * | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| US4022769A (en) * | 1974-05-13 | 1977-05-10 | Richardson-Merrell Inc. | Androst-4-en-19-ones |
| US4139617A (en) * | 1974-05-13 | 1979-02-13 | Richardson-Merrell Inc. | 19-Oxygenated-androst-5-enes for the enhancement of libido |
| DE2632677A1 (de) | 1976-07-16 | 1978-01-26 | Schering Ag | Verfahren zur herstellung von androstan-17-on-derivaten und deren verwendung |
| MA18433A1 (fr) * | 1978-05-26 | 1979-12-31 | Ciba Geigy Ag | Procede pour la synthese de la chaine laterale hydroxyacetyle de steroides du type pregnagne, nouveaux 21-hydroxy-20-oxo-17 alpha-pregnagnes et produits pharmaceutiques en renfermant |
| US4389345A (en) | 1981-10-09 | 1983-06-21 | G.D. Searle & Co. | 3-Oxoestra-17-acetonitrile and unsaturated analogs |
| US4495102A (en) * | 1982-09-03 | 1985-01-22 | G. D. Searle & Co. | Aminoalkyl steroids |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| EP0656365B1 (en) | 1993-12-02 | 1997-04-09 | Akzo Nobel N.V. | Substituted 2beta-morpholinoandrostane derivatives |
| US5661141A (en) * | 1995-03-27 | 1997-08-26 | Petrow; Vladimir | 19-oxygenated steroids as therapeutic agents |
| CZ394197A3 (cs) * | 1995-06-06 | 1998-06-17 | Cocensys, Inc. | Neuroaktivní steroidy androstanové a pregnanové řady |
| AU3967297A (en) * | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| US6855836B2 (en) | 2000-10-26 | 2005-02-15 | Jenapharm Gmbh & Co. Kg | 17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds |
| US6844456B2 (en) * | 2000-11-03 | 2005-01-18 | Washington University | Modified, hydroxy-substituted aromatic structures having cytoprotective activity |
| GR1003861B (el) * | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| MXPA05010339A (es) | 2003-03-24 | 2005-12-14 | Sterix Ltd | Derivados de estrogeno como inhibidores de la esteroide sulfatasa. |
| CN1281561C (zh) * | 2003-04-23 | 2006-10-25 | 中国科学院上海有机化学研究所 | 一种具有1，6－亚甲基－[10]－轮烯基本骨架的化合物及其用途 |
| US7781421B2 (en) | 2003-05-29 | 2010-08-24 | Washington University | Neuroactive 13, 24-cyclo-18, 21-dinorcholanes and structurally related pentacyclic steriods |
| WO2005051972A1 (en) | 2003-11-24 | 2005-06-09 | Merck & Co., Inc. | Estrogen receptor modulators |
| CN100376685C (zh) * | 2005-01-14 | 2008-03-26 | 天津科技大学 | 微生物转化法制备雌酚酮的方法 |
| JP2008538748A (ja) * | 2005-04-07 | 2008-11-06 | ハイシアム， インコーポレイテッド | 不安、物質乱用及び依存の予防のための改良型方法及び組成物 |
| DE102007027636A1 (de) | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| JP5663303B2 (ja) * | 2007-06-15 | 2015-02-04 | リサーチ トライアングル インスティテュート | Ｇａｂａレセプタークロライドイオノフォアの潜在的アロステリック調節特性を有するアンドロスタンステロイドおよびプレグナンステロイド |
| GB0711948D0 (en) | 2007-06-20 | 2007-08-01 | Bionature E A Ltd | Neurosteriod compounds |
| WO2012013816A1 (en) | 2010-07-30 | 2012-02-02 | Medexis S.A. | Compounds and methods for treating neoplasia |
| AU2011343615A1 (en) | 2010-12-15 | 2013-05-09 | Harbor Biosciences, Inc. | Methods and compounds for preparing 3alpha-oxygen substituted steroids |
| US9388210B2 (en) | 2011-02-25 | 2016-07-12 | Washington University | Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| US9851309B2 (en) | 2011-03-23 | 2017-12-26 | Satoshi Watabe | Ultra-high-sensitive assay of protein and nucleic acid and kit, and novel enzyme substrate |
| WO2013188792A2 (en) * | 2012-06-15 | 2013-12-19 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US9765110B2 (en) * | 2012-10-08 | 2017-09-19 | Washington University | Neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| HRP20181048T1 (hr) * | 2012-12-18 | 2018-08-24 | Washington University | Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja |
| US9562026B2 (en) | 2013-03-14 | 2017-02-07 | Washington University | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors |
| EP3035940B1 (en) * | 2013-08-23 | 2018-10-17 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
-
2013
- 2013-12-18 HR HRP20181048TT patent/HRP20181048T1/hr unknown
- 2013-12-18 IL IL278396A patent/IL278396B2/en unknown
- 2013-12-18 HU HUE13865411A patent/HUE039057T2/hu unknown
- 2013-12-18 CN CN201380072706.2A patent/CN105026415B/zh active Active
- 2013-12-18 JP JP2015549643A patent/JP6542127B2/ja active Active
- 2013-12-18 PT PT138654116T patent/PT2935307T/pt unknown
- 2013-12-18 RU RU2015129546A patent/RU2663665C2/ru active
- 2013-12-18 CN CN202210026684.7A patent/CN114605486A/zh active Pending
- 2013-12-18 BR BR112015014397-0A patent/BR112015014397B1/pt active IP Right Grant
- 2013-12-18 IL IL310501A patent/IL310501A/en unknown
- 2013-12-18 ES ES18162373T patent/ES2933987T3/es active Active
- 2013-12-18 MX MX2015007900A patent/MX365644B/es active IP Right Grant
- 2013-12-18 EP EP18162373.7A patent/EP3392260B1/en active Active
- 2013-12-18 NZ NZ739760A patent/NZ739760A/en unknown
- 2013-12-18 SG SG11201504848QA patent/SG11201504848QA/en unknown
- 2013-12-18 SM SM20180422T patent/SMT201800422T1/it unknown
- 2013-12-18 KR KR1020197018089A patent/KR102265408B1/ko active Active
- 2013-12-18 RS RS20180807A patent/RS57390B1/sr unknown
- 2013-12-18 LT LTEP13865411.6T patent/LT2935307T/lt unknown
- 2013-12-18 KR KR1020157019442A patent/KR101993899B1/ko active Active
- 2013-12-18 PT PT181623737T patent/PT3392260T/pt unknown
- 2013-12-18 MX MX2019006739A patent/MX388946B/es unknown
- 2013-12-18 WO PCT/US2013/076214 patent/WO2014100228A1/en not_active Ceased
- 2013-12-18 TR TR2018/08616T patent/TR201808616T4/tr unknown
- 2013-12-18 KR KR1020217017732A patent/KR102400891B1/ko active Active
- 2013-12-18 PH PH12018502141A patent/PH12018502141A1/en unknown
- 2013-12-18 SI SI201332021T patent/SI3392260T1/sl unknown
- 2013-12-18 US US14/652,717 patent/US9676812B2/en active Active
- 2013-12-18 CN CN201811630997.3A patent/CN109970833B/zh active Active
- 2013-12-18 SG SG10201809638YA patent/SG10201809638YA/en unknown
- 2013-12-18 NZ NZ709211A patent/NZ709211A/en unknown
- 2013-12-18 SG SG10201706063UA patent/SG10201706063UA/en unknown
- 2013-12-18 PL PL13865411T patent/PL2935307T3/pl unknown
- 2013-12-18 SI SI201331092T patent/SI2935307T1/en unknown
- 2013-12-18 AU AU2013361485A patent/AU2013361485B2/en active Active
- 2013-12-18 CA CA2895513A patent/CA2895513C/en active Active
- 2013-12-18 US US14/132,386 patent/US9630986B2/en active Active
- 2013-12-18 EP EP22166199.4A patent/EP4086270A1/en active Pending
- 2013-12-18 DK DK13865411.6T patent/DK2935307T3/en active
- 2013-12-18 EP EP13865411.6A patent/EP2935307B1/en active Active
- 2013-12-18 ES ES13865411.6T patent/ES2680582T3/es active Active
-
2015
- 2015-06-18 PH PH12015501404A patent/PH12015501404B1/en unknown
- 2015-06-18 IL IL239501A patent/IL239501B/en active IP Right Grant
-
2017
- 2017-03-15 US US15/459,492 patent/US10342809B2/en active Active
- 2017-05-04 US US15/586,853 patent/US20170232006A1/en not_active Abandoned
-
2018
- 2018-07-03 CY CY20181100686T patent/CY1121150T1/el unknown
- 2018-08-14 AU AU2018217213A patent/AU2018217213B2/en active Active
-
2019
- 2019-05-22 US US16/419,255 patent/US20200113916A1/en not_active Abandoned
- 2019-06-12 JP JP2019109822A patent/JP6852118B2/ja active Active
-
2020
- 2020-03-20 AU AU2020202016A patent/AU2020202016C1/en active Active
-
2021
- 2021-03-10 JP JP2021038515A patent/JP7241792B2/ja active Active
- 2021-06-21 US US17/304,433 patent/US20210308149A1/en not_active Abandoned
- 2021-12-20 AU AU2021290223A patent/AU2021290223B2/en active Active
-
2023
- 2023-02-09 US US18/107,965 patent/US20230190770A1/en not_active Abandoned
- 2023-03-07 JP JP2023034402A patent/JP7589275B2/ja active Active
-
2024
- 2024-04-08 AU AU2024202233A patent/AU2024202233A1/en not_active Abandoned
- 2024-11-13 JP JP2024197865A patent/JP2025024078A/ja active Pending